TY - JOUR
T1 - PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock
AU - Thiele, Holger
AU - Akin, Ibrahim
AU - Sandri, Marcus
AU - Fuernau, Georg
AU - de Waha, Suzanne
AU - Meyer-Saraei, Roza
AU - Nordbeck, Peter
AU - Geisler, Tobias
AU - Landmesser, Ulf
AU - Skurk, Carsten
AU - Fach, Andreas
AU - Lapp, Harald
AU - Piek, Jan J.
AU - Noc, Marko
AU - Goslar, Tomaž
AU - Felix, Stephan B.
AU - Maier, Lars S
AU - Stepinska, Janina
AU - Oldroyd, Keith
AU - Serpytis, Pranas
AU - Montalescot, Gilles
AU - Barthelemy, Olivier
AU - Huber, Kurt
AU - Windecker, Stephan
AU - Savonitto, Stefano
AU - Torremante, Patrizia
AU - Vrints, Christiaan J M
AU - Schneider, Steffen
AU - Desch, Steffen
AU - Zeymer, Uwe
AU - Voskuil, M
N1 - Publisher Copyright:
© 2017 Massachusetts Medical Society.
PY - 2017/12/21
Y1 - 2017/12/21
N2 - BACKGROUND In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial. METHODS In this multicenter trial, we randomly assigned 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. The primary end point was a composite of death or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Safety end points included bleeding and stroke. RESULTS At 30 days, the composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344 patients (45.9%) in the culprit-lesion-only PCI group and in 189 of the 341 patients (55.4%) in the multivessel PCI group (relative risk, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P=0.01). The relative risk of death in the culprit-lesion-only PCI group as compared with the multivessel PCI group was 0.84 (95% CI, 0.72 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03; P=0.07). The time to hemodynamic stabilization, the risk of catecholamine therapy and the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between the two groups. CONCLUSIONS Among patients who had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was lower among those who initially underwent PCI of the culprit lesion only than among those who underwent immediate multivessel PCI.
AB - BACKGROUND In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial. METHODS In this multicenter trial, we randomly assigned 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. The primary end point was a composite of death or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Safety end points included bleeding and stroke. RESULTS At 30 days, the composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344 patients (45.9%) in the culprit-lesion-only PCI group and in 189 of the 341 patients (55.4%) in the multivessel PCI group (relative risk, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P=0.01). The relative risk of death in the culprit-lesion-only PCI group as compared with the multivessel PCI group was 0.84 (95% CI, 0.72 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03; P=0.07). The time to hemodynamic stabilization, the risk of catecholamine therapy and the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between the two groups. CONCLUSIONS Among patients who had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was lower among those who initially underwent PCI of the culprit lesion only than among those who underwent immediate multivessel PCI.
KW - Aged
KW - Comparative Study
KW - Coronary Artery Disease
KW - Female
KW - Humans
KW - Journal Article
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Multicenter Study
KW - Myocardial Infarction
KW - Percutaneous Coronary Intervention
KW - Randomized Controlled Trial
KW - Renal Insufficiency
KW - Renal Replacement Therapy
KW - Research Support, Non-U.S. Gov't
KW - Risk
KW - Shock, Cardiogenic
KW - Time-to-Treatment
U2 - 10.1056/NEJMoa1710261
DO - 10.1056/NEJMoa1710261
M3 - Article
C2 - 29083953
SN - 0028-4793
VL - 377
SP - 2419
EP - 2432
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 25
ER -